Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809787 | 1.00 | CKS1B (0.53) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL31254501 | 0.81 | CKS1B (0.63) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL1480048 | 0.81 | CKS1B (0.63) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL24165227 | 0.80 | CKS1B (0.48) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL24507711 | 0.78 | GPR119 (0.54) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL31254495 | 0.77 | CKS1B (0.66) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL18163269 | 0.76 | MAP4K4 (0.54) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL29282426 | 0.76 | CKS1B (0.53) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL22576378 | 0.75 | CKS1B (0.53) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL30501971 | 0.75 | CKS1B (0.53) | CKS1BSKP1SKP2MAP4K4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CKS1B 108/4885SKP1 1125/4885SKP2 580/4885 |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CKS1B 108/4885SKP1 1125/4885SKP2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.